India’s rise from 123rd to 8th position globally in contributions to the World Health Organization’s pharmacovigilance database reflects a major strengthening of the country’s drug safety and regulatory systems, with significant progress driven by the Pharmacovigilance Programme of India under the Indian Pharmacopoeia Commission.
Union Health Minister Jagat Prakash Nadda highlighted that the turnaround from India’s ranking during 2009–2014 to its current global standing in 2025 underscores sustained improvements in adverse drug reaction reporting, regulatory vigilance, and patient safety oversight, commending the Indian Pharmacopoeia Commission and the PvPI team for building a stronger pharmacovigilance ecosystem anchored in quality assurance and public health protection.
He also drew attention to key regulatory milestones accompanying the release of Indian Pharmacopoeia 2026, including the first-time inclusion of 20 blood component monographs related to transfusion medicine. These additions have been incorporated in line with the Drugs and Cosmetics (Second Amendment) Rules, 2020, marking a significant step in standardising and strengthening quality norms for blood and blood products in India.
He further noted that the Indian Pharmacopoeia 2026 reflects the government’s continued focus on reinforcing healthcare systems and regulatory institutions under the leadership of Prime Minister Narendra Modi, with an emphasis on quality, transparency, and public welfare. The tenth edition of the pharmacopoeia is expected to further enhance pharmaceutical quality standards, reinforce the national regulatory framework, and strengthen India’s position in the global pharmaceutical landscape.
According to Union Health Secretary Punya Salila Srivastava, the release of Indian Pharmacopoeia 2026 represents an important advancement in India’s pharmaceutical regulatory ecosystem, underlining the role of a robust, science-based pharmacopoeia in ensuring the availability of safe, effective, and quality-assured medicines.
She emphasised that the continuous updating and harmonisation of pharmacopoeial standards demonstrate India’s commitment to global best practices, patient safety, and regulatory excellence, while supporting the country’s expanding role in the global pharmaceutical supply chain.
